1
|
Carr R, Ozdag H, Tekin N, Morris T, Conget P, Bruna F, Timar B, Gagyi E, Basak R, Naik O, Auewarakul C, Srithana N, Dimamay MP, Natividad F, Chung JK, Belder N, Kuzu I, Omidvar N, Paez D, Padua RA. The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. Leuk Lymphoma 2016; 58:1178-1183. [PMID: 27724056 DOI: 10.1080/10428194.2016.1231308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Addressing the global burden of cancer, understanding its diverse biology, and promoting appropriate prevention and treatment strategies around the world has become a priority for the United Nations and International Atomic Energy Agency (IAEA), the WHO, and International Agency for Research on Cancer (IARC). The IAEA sponsored an international prospective cohort study to better understand biology, treatment response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income countries across five UN-defined geographical regions. We report an analysis of biological variation in DLBCL across seven ethnic and environmentally diverse populations. In this cohort of 136 patients treated to a common protocol, we demonstrate significant biological differences between countries, characterized by a validated prognostic gene expression score (p < .0001), but International Prognostic Index (IPI)-adjusted survivals in all participating countries were similar. We conclude that DLBCL treatment outcomes in these populations can be benchmarked to international standards, despite biological heterogeneity.
Collapse
Affiliation(s)
- Robert Carr
- a Department of Haematology , Guy's & St. Thomas' Hospital, King's College , London , UK
| | - Hilal Ozdag
- b Biotechnology Institute, Ankara University , Ankara , Turkey
| | - Nilgun Tekin
- b Biotechnology Institute, Ankara University , Ankara , Turkey
| | - Timothy Morris
- c Medical Research Council Clinical Trials Unit , University College London , London , UK
| | - Paulette Conget
- d Facultad de Medicina Clínica Alemana, Universidad del Desarrollo , Santiago , Chile
| | - Flavia Bruna
- d Facultad de Medicina Clínica Alemana, Universidad del Desarrollo , Santiago , Chile
| | - Botond Timar
- e 1st Department of Pathology and Experimental Cancer Research , Semmelweis University , Budapest , Hungary
| | - Eva Gagyi
- e 1st Department of Pathology and Experimental Cancer Research , Semmelweis University , Budapest , Hungary
| | - Ranjan Basak
- f Department of Medical Oncology and Pathology , Tata Memorial Hospital , Mumbai , India
| | - Omkar Naik
- f Department of Medical Oncology and Pathology , Tata Memorial Hospital , Mumbai , India
| | | | | | - Mark Pierre Dimamay
- h Research and Biology Division , St. Luke's Medical Centre , Manila , Philippines
| | - Filipinas Natividad
- h Research and Biology Division , St. Luke's Medical Centre , Manila , Philippines
| | - June-Key Chung
- i Oncology Clinic , Seoul National University Hospital , Seoul , Republic of Korea
| | - Nevin Belder
- b Biotechnology Institute, Ankara University , Ankara , Turkey
| | - Isinsu Kuzu
- j Department of Pathology , Ankara University , Ankara , Turkey
| | - Nader Omidvar
- k Department of Haematology , University of Cardiff , Cardiff , UK
| | - Diana Paez
- l Nuclear Medicine Section, International Atomic Energy Agency , Vienna , Austria
| | - Rose Ann Padua
- m INSERM 1131 , University Paris-Diderot, Hôpital Saint-Louis , Paris , France
| |
Collapse
|